Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

NTCB02-1

Phase 3Small molecule

YYuhan Corporation

NTCB02-1 is one of 2 small molecule programs targeting Parenteral Nutrition. It is currently in Phase 3.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parenteral NutritionRecruiting

Parenteral NutritionPhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Parenteral Nutrition

#DrugCompanyPhaseTrials

NTCB02-1

YYuhan Corporation

Choline Chloride

NNorthwestern University

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Parenteral Nutrition1 trial

Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral Nutrition

Recruiting·YYuhan Corporation·Phase 3·NCT06625957·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NTCB02-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NTCB02-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NTCB02-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yuhan Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: YYuhan Corporation

Related News